Galapagos N.V. (AS:GLPG) — Market Cap & Net Worth
Market Cap & Net Worth: Galapagos N.V. (GLPG)
Galapagos N.V. (AS:GLPG) has a market capitalization of $1.55 Billion (€1.33 Billion) as of September 19, 2026. Listed on the AS stock exchange, this Netherlands-based company holds position #7133 globally and #48 in its home market, demonstrating a 13.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galapagos N.V.'s stock price €26.90 by its total outstanding shares 65897071 (65.90 Million). Also see GLPG current and non-current assets for a full breakdown of the balance sheet.
Galapagos N.V. Market Cap History: 2015 to 2026
Galapagos N.V.'s market capitalization history from 2015 to 2026. Data shows change from $4.37 Billion to $2.07 Billion (-4.77% CAGR). Also see Galapagos N.V. cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Galapagos N.V. is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMX-Index
AMX
|
$87.75 Billion | 1.77% | #17 of 25 |
|
BEL-20 INDEX
BEL20
|
$375.29 Billion | 0.41% | #20 of 20 |
|
BEL-20 INDEX
BFX
|
$375.29 Billion | 0.41% | #20 of 20 |
|
BEL All Share
BSPT
|
$835.18 Billion | 0.19% | #39 of 108 |
Weight: Galapagos N.V.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galapagos N.V. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galapagos N.V.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GLPG live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.94x
Galapagos N.V.'s market cap is 1.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.72x
Galapagos N.V.'s market cap is 6.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.69 Billion | $129.52 Million | $54.01 Million | 36.25x | 86.92x |
| 2017 | $6.08 Billion | $127.09 Million | -$115.70 Million | 47.88x | N/A |
| 2018 | $6.21 Billion | $288.84 Million | -$29.26 Million | 21.49x | N/A |
| 2019 | $14.37 Billion | $844.99 Million | $149.84 Million | 17.00x | 95.89x |
| 2020 | $6.20 Billion | $478.05 Million | -$311.00 Million | 12.97x | N/A |
| 2021 | $3.79 Billion | $484.85 Million | -$125.42 Million | 7.82x | N/A |
| 2022 | $3.19 Billion | $505.28 Million | -$217.99 Million | 6.30x | N/A |
| 2023 | $2.85 Billion | $239.72 Million | $211.70 Million | 11.89x | 13.46x |
| 2024 | $2.04 Billion | $275.65 Million | $74.08 Million | 7.41x | 27.58x |
| 2025 | $2.16 Billion | $1.11 Billion | $320.88 Million | 1.94x | 6.72x |
Competitor Companies of GLPG by Market Capitalization
Companies near Galapagos N.V. in the global market cap rankings as of September 19, 2026. Review GLPG tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Galapagos N.V. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Galapagos N.V. Historical Marketcap From 2015 to 2026
Between 2015 and today, Galapagos N.V.'s market cap moved from $4.37 Billion to $ 2.07 Billion, with a yearly change of -4.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.07 Billion | -3.93% |
| 2025 | €2.16 Billion | +5.58% |
| 2024 | €2.04 Billion | -28.30% |
| 2023 | €2.85 Billion | -10.54% |
| 2022 | €3.19 Billion | -15.99% |
| 2021 | €3.79 Billion | -38.84% |
| 2020 | €6.20 Billion | -56.85% |
| 2019 | €14.37 Billion | +131.50% |
| 2018 | €6.21 Billion | +2.00% |
| 2017 | €6.08 Billion | +29.60% |
| 2016 | €4.69 Billion | +7.36% |
| 2015 | €4.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Galapagos N.V. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.55 Billion USD |
| MoneyControl | $1.55 Billion USD |
| MarketWatch | $1.55 Billion USD |
| marketcap.company | $1.55 Billion USD |
| Reuters | $1.55 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more